Cargando…

Perioperative safety and feasibility outcomes of stage IIIA-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy: a retrospective study

BACKGROUND: We sought to determine the perioperative safety and feasibility outcomes of stage IIIA (N2) non-small cell lung cancer (NSCLC) following neoadjuvant immunotherapy or neoadjuvant chemotherapy. METHODS: The clinical details of patients who attended the Affiliated Hospital of Qingdao Univer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Zhangfeng, Wu, Zhe, Qin, Yi, Zhao, Yandong, Xuan, Yunpeng, Qiu, Tong, Liu, Ao, Dong, Yanting, Su, Wenhao, Du, Wenxing, Yun, Tianxiang, Wang, Lingjie, Liu, Dahai, Sun, Lili, Jiao, Wenjie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106052/ https://www.ncbi.nlm.nih.gov/pubmed/33987383 http://dx.doi.org/10.21037/atm-21-1141

Ejemplares similares

circFBXW7 attenuates malignant progression in lung adenocarcinoma by sponging miR-942-5p
por: Dong, Yanting, et al.
Publicado: (2021)

Different efficacy in the non-small cell lung cancer patient with bilateral synchronous lesions treated with neoadjuvant gefitinib therapy: a case report
por: Du, Wenxing, et al.
Publicado: (2020)

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
por: Huang, Zhangfeng, et al.
Publicado: (2020)

Predictive value of a novel Asian lung cancer screening nomogram based on artificial intelligence and epidemiological characteristics
por: Liu, Dahai, et al.
Publicado: (2021)

Circ-AASDH functions as the progression of early stage lung adenocarcinoma by targeting miR-140-3p to activate E2F7 expression
por: Wang, Yuanyong, et al.
Publicado: (2021)

The impact of neoadjuvant immunotherapy on perioperative outcomes and survival after esophagectomy for esophageal cancer
por: Wong, Lye-Yeng, et al.
Publicado: (2023)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Asynchrony of primary tumor and mediastinal lymph nodes response after neoadjuvant immunotherapy plus chemotherapy in a patient with stage IIIA non–small-cell lung cancer: a case report
por: Liu, Yunpeng, et al.
Publicado: (2021)

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
por: Marron, Thomas U, et al.
Publicado: (2022)

Single utility port approach in robot‐assisted sleeve segmentectomy for bronchial carcinoid tumor
por: Liu, Ao, et al.
Publicado: (2022)

Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study
por: Zhang, Hai, et al.
Publicado: (2023)

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
por: Garcia, Diogo, et al.
Publicado: (2021)

Perioperative versus total neoadjuvant chemotherapy in gastric cancer
por: Yang, Jessica, et al.
Publicado: (2023)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
por: Dai, Huiru, et al.
Publicado: (2022)

Neoadjuvant immunotherapy for resectable esophageal cancer: A review
por: Li, Qing, et al.
Publicado: (2022)

Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
por: Cheng, Jiahan, et al.
Publicado: (2022)

The long-term oncologic outcomes of robot-assisted bronchial single sleeve lobectomy for 104 consecutive patients with centrally located non-small cell lung cancer
por: Liu, Ao, et al.
Publicado: (2022)

Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer
por: Liang, Wenhua, et al.
Publicado: (2020)

Efficacy and Safety of Neoadjuvant Targeted Therapy vs. Neoadjuvant Chemotherapy for Stage IIIA EGFR-Mutant Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Chen, Dong, et al.
Publicado: (2021)

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
por: Yang, Chang, et al.
Publicado: (2020)

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
por: Yi, Chengxiang, et al.
Publicado: (2019)

Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
por: Peyrottes, Arthur, et al.
Publicado: (2021)

Lung Cancer Surgery after Neoadjuvant Immunotherapy
por: Stefani, Dirk, et al.
Publicado: (2021)

Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC
por: Roller, John F., et al.
Publicado: (2022)

Anaesthesia after neoadjuvant chemotherapy, immunotherapy or radiotherapy
por: Groenewold, M.D., et al.
Publicado: (2022)

Neoadjuvant immunotherapy of locoregionally advanced solid tumors
por: Tarhini, Ahmad A, et al.
Publicado: (2022)

Neoadjuvant immunotherapy in primary and metastatic colorectal cancer
por: Kanani, A, et al.
Publicado: (2021)

Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle invasive bladder cancer
por: Chen, Hualin, et al.
Publicado: (2022)

Neoadjuvant chemoimmunotherapy as a potential therapeutic option in NSCLC UICC stage IIIA with multilevel N2 disease
por: Menghesha, Hruy, et al.
Publicado: (2022)

Safety and effectiveness of neoadjuvant immunotherapy combined with chemotherapy followed by surgical resection in patients with stage I–IIIA small-cell lung cancer: a retrospective single-arm clinical trial
por: Liu, Jiacong, et al.
Publicado: (2022)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
por: Li, Xin, et al.
Publicado: (2022)

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial
por: Eichhorn, Florian, et al.
Publicado: (2019)

Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer
por: Zhou, Long, et al.
Publicado: (2023)

Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report
por: Chen, Caroline Y., et al.
Publicado: (2021)

Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
por: Reyes, Roxana, et al.
Publicado: (2021)

Neoadjuvant osimertinib and chemotherapy for stage IIIA primary pulmonary carcinosarcoma with EGFR 19DEL mutation: A case report
por: Wang, Hongming, et al.
Publicado: (2023)

Multi‐organs perioperative immune‐related adverse events and postoperative bronchial anastomotic fistula in a patient receiving neoadjuvant immunotherapy with NSCLC
por: Xu, Yuan, et al.
Publicado: (2022)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Neoadjuvant immunotherapy in breast cancer: a paradigm shift?
por: Fountzila, Elena, et al.
Publicado: (2020)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rc6bt65oecc0k88edjqjb7vggq